We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does rimonabant independently affect free fatty acid and glucose metabolism?
- Authors
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M; Triay, Jessica; Mundi, Manpreet; Klein, Samuel; Toledo, Frederico G; Smith, Steven R; Abu-Lebdeh, Haitham; Jensen, Michael
- Abstract
<bold>Context: </bold>Endocannabinoid receptor 1 blockade is proposed to improve metabolic complications of obesity via central and peripheral effects.<bold>Objective: </bold>Our objective was to test whether rimonabant improves insulin regulation of free fatty acid and glucose metabolism after controlling for fat loss.<bold>Design: </bold>This was a double-blind, placebo-controlled substudy of the visceral fat reduction assessed by computed tomography scan on rimonabant (VICTORIA) trial.<bold>Participants and Setting: </bold>Sixty-seven abdominally obese, metabolic syndrome volunteers age 35-70 yr participated at academic medical center general clinical research centers.<bold>Intervention: </bold>Intervention included a 12-month lifestyle weight management program plus rimonabant 20 mg/d or placebo.<bold>Main Outcome Measures: </bold>Body composition and two-step euglycemic, hyperinsulinemic clamp before and after intervention were performed. Insulin sensitivity was assessed as insulin concentration needed to suppress by 50% palmitate concentration [IC50(palmitate)], flux [IC50(palmitate)f], and hepatic glucose output [IC50(HGO)] and as insulin-stimulated glucose disposal (Δ glucose disappearance per Δ insulin concentration--glucose slope).<bold>Results: </bold>Body fat decreased by 4.5±2.9% (SD) in the rimonabant and 1.9±4.5% in the placebo group (P<0.005). The primary [improvement in IC50(palmitate) and IC50(palmitate)f] and secondary [improvement in IC50(HGO) and glucose slope] outcomes were not significantly different between the rimonabant and placebo groups. Post hoc analyses revealed that 1) changes in body mass index (BMI) and IC50(palmitate) were correlated (P=0.005) in the rimonabant group; this relationship was not significantly different from placebo when controlling for greater BMI loss (P=0.5); 2) insulin-regulated glucose disposal improved in both groups (P=0.002) and correlated with changes in BMI.<bold>Conclusions: </bold>Improvements observed in insulin regulation of free fatty acid and glucose metabolism with rimonabant treatment in humans was not greater than that predicted by weight loss alone.
- Publication
Journal of Clinical Endocrinology & Metabolism, 2012, Vol 97, Issue 3, p819
- ISSN
0021-972X
- Publication type
journal article
- DOI
10.1210/jc.2011-2486